News
05-19-2011, 07:10 AM
Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.
More... (http://www.news-medical.net/news/20110519/Enzon-to-discontinue-PEG-SN38-clinical-program-in-metastatic-colorectal-cancer.aspx)
More... (http://www.news-medical.net/news/20110519/Enzon-to-discontinue-PEG-SN38-clinical-program-in-metastatic-colorectal-cancer.aspx)